Results 11 to 20 of about 67,431 (260)

Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose

Blood and Lymphatic Cancer: Targets and Therapy, 2015
Joanna Waclaw,1 Tomasz Sacha,1 Tomasz Stoklosa,21Department of Hematology, Jagiellonian University Collegium Medicum, Kraków, 2Department of Immunology, Medical University of Warsaw, Warsaw, Poland Abstract: Imatinib was the first tyrosine kinase
Waclaw J, Sacha T, Stoklosa T
doaj   +1 more source

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

Biologics: Targets & Therapy, 2009
Radhakrishnan Ramchandren, Charles A SchifferDivision of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USAAbstract: The development of imatinib for the treatment of chronic myeloid leukemia (CML ...
Radhakrishnan Ramchandren, Charles A Schiffer   +1 more
doaj   +1 more source

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Dempke, Wolfram, Linke, Rolf
core   +1 more source

Imatinib Mesylate Reduces Voiding Frequency in Female Mice With Acute Cyclophosphamide-Induced Cystitis

Frontiers in Systems Neuroscience, 2022
Lamina propria interstitial cells that express the tyrosine kinase receptor, platelet-derived growth factor receptor alpha (PDGFRα) may play a role in urinary sensory signaling.
Megan E. Perkins, Beatrice M. Girard, Susan E. Campbell, Margaret A. Vizzard   +3 more
doaj   +1 more source

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor

Cells, 2020
Metabolic reprogramming is a hallmark of cancer cells in response to targeted therapy. Decreased glycolytic activity with enhanced mitochondrial respiration secondary to imatinib has been shown in imatinib-sensitive gastrointestional stromal tumors (GIST)
Wen-Kuan Huang, Jiwei Gao, Ziqing Chen, Hao Shi, Juan Yuan, Huanhuan L. Cui, Chun-Nan Yeh, Robert Bränström, Catharina Larsson, Shuijie Li, Weng-Onn Lui   +10 more
doaj   +1 more source

Response to imatinib rechallenge in a patient with a recurrent gastrointestinal stromal tumor after adjuvant therapy: a case report

Journal of Medical Case Reports, 2011
Introduction Adjuvant imatinib improves recurrence-free survival of patients following resection of primary KIT-positive gastrointestinal stromal tumors.
Kang Yoon-Koo
doaj   +1 more source

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
Holyoake, T., Tessa Holyoake, Michor Franziska, Michor, F., Holyoake Tessa, Clarkson Bayard, Foo, J., Mark W Drummond, Franziska Michor, Bayard Clarkson, Foo Jasmine, Drummond, M.W., Jasmine Foo, Clarkson, B., Drummond Mark W.   +14 more
core   +1 more source

Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.

PLoS ONE, 2011
Challenges today concern chronic myeloid leukemia (CML) patients resistant to imatinib. There is growing evidence that imatinib-resistant leukemic cells present abnormal glucose metabolism but the impact on mitochondria has been neglected. Our work aimed
Jérome Kluza, Manel Jendoubi, Caroline Ballot, Abir Dammak, Aurélie Jonneaux, Thierry Idziorek, Sami Joha, Véronique Dauphin, Myriam Malet-Martino, Stéphane Balayssac, Patrice Maboudou, Gilbert Briand, Pierre Formstecher, Bruno Quesnel, Philippe Marchetti   +14 more
doaj   +1 more source

Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: a case report [PDF]

, 2008
Introduction: A duodenal Gastrointestinal Stromal Tumour (GIST) is a rare finding and until recently advanced disease had a poor prognosis. A PubMed search revealed no reports of more than five years survival of inoperable GIST on chemotherapy with WHO ...
Morrissey, John R., Bhattacharya Sayantan, Morrissey John, Choudhury Amit, Bhattacharya, Sayantan, Ravi, Srinivasan, Mathew, G. (George), Ravi Srinivasan, Mathew George, Choudhury, Amit Kumar   +9 more
core   +1 more source

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

Haematologica, 2016
The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a follow-up of ≥12 months were analyzed.
Sung-Eun Lee, Soo Young Choi, Hye-Young Song, Soo-Hyun Kim, Mi-Yeon Choi, Joon Seong Park, Hyeoung-Joon Kim, Sung-Hyun Kim, Dae Young Zang, Sukjoong Oh, Hawk Kim, Young Rok Do, Jae-Yong Kwak, Jeong-A Kim, Dae-Young Kim, Yeung-Chul Mun, Won Sik Lee, Myung Hee Chang, Jinny Park, Ji Hyun Kwon, Dong-Wook Kim   +20 more
doaj   +1 more source